Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register

Explore journal

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 15492 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	2. 14877 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	3. 10232 Accesses	Research Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui, Rachelle S Doody Alzheimers Res Ther 2009, 1:7 (21 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Persistent treatment with cholinesterase inhibitors and/or memantine had a positive impact on Alzheimers disease (AD) progression by multiple cognitive and functional outcome measures.
	4. 8032 Accesses	Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nilüfer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
	5. 7803 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed
	6. 7608 Accesses	Review Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil, Carol Brayne Alzheimers Res Ther 2009, 1:4 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephan et al. review the concept of ‘vascular cognitive impairment, no dementia’ (VCIND) and its application for screening individuals at increased risk of dementia secondary to vascular disease and its risk factors.
	7. 7301 Accesses	Review Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Roy O Weller, Stephen D Preston, Malavika Subash, Roxana O Carare Alzheimer's Research & Therapy 2009, 1:6 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Weller et al. highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies for Alzheimer's disease.
	8. 7216 Accesses	Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
	9. 6910 Accesses	Commentary Alzheimer's disease therapeutic research: the path forward Paul S Aisen Alzheimers Res Ther 2009, 1:2 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Despite recent negative trial results, a clear path forward is emerging in Alzheimer’s disease therapeutic research using newly available tools to allow the study of new treatments at earlier stages in the disease process.
	10. 6783 Accesses	Research A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:29 (15 October 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A Quick Test of cognitive speed is twice as sensitive as the mini-mental state examination in evaluating cholinesterase inhibitor treatment in Alzheimer’s disease patients, indicating its potential usefulness in the primary care setting.
	11. 6353 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	12. 5659 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	13. 5438 Accesses	Review Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases Todd E Golde, Victor M Miller Alzheimers Res Ther 2009, 1:5 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Golde and Miller propose an integrative hypothesis that provides new insights into how a variety of misfolded protein aggregates can result in neurodegeneration.
	14. 4845 Accesses	Commentary Can novel therapeutics halt the amyloid cascade? Niels D Prins, Pieter Visser, Philip Scheltens Alzheimer's Research & Therapy 2010, 2:5 (9 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Prins and colleagues discuss the negative results of the recent bapineuzumab and tarenflurbil trials, the lessons learnt from them and comment on the potential implications for future novel therapeutics.
	15. 4795 Accesses	Research A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers, Kaj Blennow Alzheimer's Research & Therapy 2010, 2:7 (29 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta isoforms in cerebrospinal fluid increase during gamma-secretase inhibitor treatment in Alzheimer's disease (AD), and may be used as novel sensitive biomarkers to monitor the biochemical effect in clinical trials.
	16. 4748 Accesses	Review Angiotensins and Alzheimer's disease: a bench to bedside overview Patrick G Kehoe Alzheimers Res Ther 2009, 1:3 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Kehoe proposes angiotensins and associated enzymatic pathways as important mediators of recognized but undefined links between blood pressure and Alzheimer’s disease.
	17. 4632 Accesses	Review Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions Larry G Brooks, David A Loewenstein Alzheimer's Research & Therapy 2010, 2:28 (29 September 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary From mild cognitive impairment through to dementia, Alzheimer’s disease is a continuous process and it is likely that multivariate models incorporating cognitive measures, functional variables and biomarker data are best suited to assess this longitudinal change.
	18. 4272 Accesses	Commentary Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander? Zaldy S Tan, Sudha Seshadri Alzheimer's Research & Therapy 2010, 2:6 (12 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Tan and Seshadri consider evidence linking inflammation to Alzheimer’s disease risk, discussing the growing body of evidence that suggests inflammatory biomarkers could be used to risk-stratify people for preventative/therapeutic interventions.
	19. 4194 Accesses	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.
	20. 3940 Accesses	Review Role of structural MRI in Alzheimer's disease Prashanthi Vemuri, Clifford R Jack Alzheimer's Research & Therapy 2010, 2:23 (31 August 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Structural MRI (sMRI) plays many roles as an Alzheimer’s disease (AD) biomarker and is of both prognostic and diagnostic value, but further work is needed in order to integrate it with other clinical measures.
	21. 3924 Accesses	Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
	22. 3835 Accesses	Review Can aerobic exercise protect against dementia? Neill R Graff-Radford Alzheimer's Research & Therapy 2011, 3:6 (28 February 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Aerobic exercise may be protective of brain health according to recent basic research and epidemiological studies, but prospective blinded studies are needed to evaluate its role in protecting against dementia.
	23. 3775 Accesses	Research Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley, Li-Ru Zhao Alzheimer's Research & Therapy 2011, 3:8 (15 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stem cell factor and granulocyte-colony stimulating factor limit beta-amyloid accumulation in a mouse model suggesting treatment with hematopoeitic growth factors may offer a new therapeutic approach for Alzheimer’s disease.
	24. 3754 Accesses	Editorial Welcome to Alzheimer's Research & Therapy Ann Donnelly, Doug Galasko, Todd Golde, Frances Mulvany, Gordon Wilcock Alzheimers Res Ther 2009, 1:1 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Douglas Galasko, Todd Golde and Gordon Wilcock, Editors-in-chief, introduce Alzheimer’s Research & Therapy, the major forum for translational research into Alzheimer’s disease.
	25. 3666 Accesses	Commentary Increasing incidence of dementia in the oldest old: evidence and implications Bryan D James, Julie A Schneider Alzheimer's Research & Therapy 2010, 2:9 (13 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The implications of a study suggesting an exponential rise in dementia in persons 90 years and older are discussed and compared to other studies reporting a slowing incidence.